GO:0045824 negative regulation of innate immune response: Signaling Checkpoints, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045824 describes any biological process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response.
• Negative regulation is essential to prevent excessive inflammation and autoimmunity while preserving effective host defense.
• Key mechanisms include proteasomal degradation and deubiquitination of innate immune signaling proteins, phosphatase-mediated inactivation of MAP kinases, and ubiquitin-dependent control of adaptor proteins such as TRIF and MAVS.
• Viruses and intracellular bacteria exploit these negative regulatory pathways to evade immunity, as shown for foot-and-mouth disease virus VP1 targeting YTHDF2 and Helicobacter pylori modulating innate responses.
• Dysregulation of negative regulators such as VAPB, RNF5, MKP-1, and YTHDF2 is linked to inflammatory diseases, cancer, and impaired pathogen clearance [3,6,7,5].
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulatory nodes in innate immunity.
Description
The innate immune response is the first line of defense against pathogens, but it must be tightly controlled to avoid tissue damage and autoimmunity. GO:0045824, negative regulation of innate immune response, encompasses all processes that stop, prevent, or reduce the frequency, rate or extent of this response. This term is critical for understanding how cells balance effective antimicrobial defense with immune homeostasis. Negative regulation occurs at multiple levels, including proteasomal degradation and deubiquitination of signaling intermediates, phosphatase-mediated inactivation of MAP kinases, and ubiquitin-dependent modulation of adaptor proteins such as TRIF and MAVS. Viruses and bacteria often hijack these pathways to evade host immunity, as exemplified by foot-and-mouth disease virus VP1 degrading YTHDF2 to regulate IRF3 activity and Helicobacter pylori modulating innate responses. Consequently, researchers studying infection, inflammation, cancer, and autoimmunity require a precise understanding of GO:0045824 and the genes that execute it.
negative regulation of innate immune response At A Glance
| GO ID | GO:0045824 |
|---|---|
| GO term | negative regulation of innate immune response |
| Ontology | biological_process |
| Synonym | down regulation of innate immune response; down-regulation of innate immune response; downregulation of innate immune response; inhibition of innate immune response |
| Major function | Dampening or terminating innate immune signaling to prevent excessive inflammation and autoimmunity while allowing pathogen clearance |
| Key mechanisms | Proteasomal degradation, deubiquitination, phosphatase-mediated inactivation, ubiquitin editing of adaptors |
| Representative regulators | VAPB, RNF5, MKP-1 (DUSP1), YTHDF2, TRIF, MAVS, and deubiquitinating enzymes |
| Disease relevance | Inflammatory disorders, autoimmunity, cancer, and pathogen immune evasion |
What Is GO:0045824?
According to the Gene Ontology, GO:0045824 (negative regulation of innate immune response) is defined as any process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response. This biological process includes molecular mechanisms such as deubiquitination, proteasomal degradation, phosphatase activity, and sequestration of signaling molecules, all of which dampen innate immune signaling pathways triggered by pattern recognition receptors.
Why Is negative regulation of innate immune response Important in Cell Biology?
GO:0045824 is essential because unchecked innate immune activation can cause chronic inflammation, tissue damage, and autoimmune disease, while excessive negative regulation can lead to immunodeficiency or pathogen persistence. Understanding this process illuminates how hosts balance defense and tolerance, and how pathogens exploit negative regulators to evade immunity. For example, VAPB acts as a negative regulator of STING-mediated signaling, RNF5 negatively regulates MAVS-mediated antiviral responses, and MKP-1 controls MAP kinase-driven inflammatory gene expression. These examples underscore the therapeutic potential of targeting negative regulatory nodes in infectious and inflammatory diseases.
• Prevents autoimmunity and chronic inflammation by terminating innate immune signaling after pathogen clearance.
• Controls the intensity and duration of cytokine and interferon responses.
• Enables pathogens such as foot-and-mouth disease virus and Helicobacter pylori to evade host immunity [5,4].
• Dysregulation is implicated in cancer, where negative regulators can suppress antitumor immunity.
• Provides targets for host-directed therapies against infectious diseases.
• Explains inter-individual variability in inflammatory disease susceptibility.
• Guides development of vaccines and immunomodulators.
• Reveals mechanisms of immune evasion by intracellular bacteria.
• Informs CRISPR-based screens for regulators of innate immunity.
• Highlights the importance of ubiquitin and phosphorylation switches in immune homeostasis [8,6].
What Happens During negative regulation of innate immune response?
Initiation of negative feedback after PRR activation
In simple terms: Once immune sensors are triggered, the cell quickly turns on brakes to avoid overreaction.
Following pattern recognition receptor (PRR) activation, innate immune signaling cascades induce the expression of negative regulators that prevent excessive or prolonged inflammation. These regulators include deubiquitinating enzymes, E3 ligases, and phosphatases that target key signaling intermediates. For example, MAP kinase phosphatase-1 (MKP-1) is induced upon Toll-like receptor (TLR) stimulation and dephosphorylates MAP kinases to dampen inflammatory cytokine production. Similarly, the E3 ligase RNF5 negatively regulates MAVS-mediated antiviral signaling by promoting its degradation.
Ubiquitin-dependent degradation of signaling proteins
In simple terms: Tagging immune proteins with ubiquitin sends them to the cellular trash can.
Proteasomal degradation of innate immune signaling proteins is a major negative regulatory mechanism. The ubiquitin-proteasome system marks activated signaling molecules such as IRF3, TRIF, and STING for degradation, thereby terminating the response. For instance, TRIF-mediated signaling is regulated by K27-linked polyubiquitination and deubiquitination, which control its stability and downstream interferon induction. Viral proteins can exploit this system; foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity and enhance viral replication.
Deubiquitination and editing of signaling complexes
In simple terms: Enzymes can remove ubiquitin tags to switch off immune signals.
Deubiquitinating enzymes (DUBs) counteract ubiquitin-mediated activation by removing ubiquitin chains from signaling proteins. This editing function is critical for preventing spontaneous immune activation. For example, the deubiquitinase activity that removes K27-linked chains from TRIF negatively regulates TLR3/4-mediated innate immune responses. Similarly, deubiquitination of STING and MAVS controls the duration of antiviral signaling [1,7].
Phosphatase-mediated inactivation of kinases
In simple terms: Phosphatases erase phosphate marks to shut down kinase pathways.
MAP kinase phosphatases, such as MKP-1, dephosphorylate and inactivate JNK, p38, and ERK, thereby reducing the transcription of inflammatory genes. This negative feedback loop is essential for resolving inflammation and preventing tissue damage. MKP-1 deficiency leads to hyperinflammatory responses, demonstrating its non-redundant role in negative regulation.
Pathogen-driven subversion of negative regulation
In simple terms: Germs can hijack the brakes to escape immune attack.
Pathogens have evolved strategies to enhance negative regulation of innate immunity. Helicobacter pylori modulates innate immune signaling in gastric epithelial cells to establish persistent infection. Foot-and-mouth disease virus VP1 targets YTHDF2 for autophagic degradation, which in turn regulates IRF3 activity and promotes viral replication. These examples illustrate how understanding GO:0045824 is crucial for infectious disease research.
Key Genes Involved in GO:0045824 negative regulation of innate immune response
The following genes and proteins are experimentally validated participants in negative regulation of innate immune response (GO:0045824).
| Gene | Major Role | Research Relevance |
|---|---|---|
| VAPB | Negative regulator of STING-mediated innate immune signaling | Target for modulating antiviral and antitumor immunity |
| RNF5 | E3 ligase that negatively regulates MAVS-mediated antiviral response | Controls mitochondrial antiviral signaling |
| DUSP1 (MKP-1) | Phosphatase that inactivates MAP kinases | Central negative regulator of TLR-induced inflammation |
| YTHDF2 | m6A reader targeted for degradation to regulate IRF3 activity | Viral evasion mechanism via autophagy |
| TRIF (TICAM1) | Adaptor protein regulated by K27-linked polyubiquitination/deubiquitination | Key node in TLR3/4 negative regulation |
| MAVS | Mitochondrial adaptor negatively regulated by RNF5 | Antiviral signaling checkpoint |
| STING (TMEM173) | ER adaptor negatively regulated by VAPB | Target for immunotherapy |
| IRF3 | Transcription factor whose activity is modulated by YTHDF2 degradation | Viral evasion and interferon control |
| NFKB1 | Transcription factor subunit indirectly controlled by negative regulators | Inflammation resolution |
| MAPK14 (p38) | Kinase inactivated by MKP-1 | Inflammatory cytokine production |
| MAPK8 (JNK) | Kinase inactivated by MKP-1 | Stress and inflammatory signaling |
| MAPK3 (ERK1) | Kinase inactivated by MKP-1 | Innate immune gene transcription |
| USP family DUBs | Deubiquitinate signaling proteins to terminate responses | Broad negative regulation |
| OTU family DUBs | Deubiquitinate signaling proteins to terminate responses | Broad negative regulation |
| H. pylori effectors | Modulate host innate immune signaling | Bacterial persistence |
| FMDV VP1 | Degrades YTHDF2 to regulate IRF3 | Viral replication strategy |
| Neutrophil regulators | Control neutrophil-driven innate immunity | Host defense and inflammation |
How Is negative regulation of innate immune response Regulated?
Negative regulation of innate immune response is itself tightly regulated at multiple levels. Transcriptionally, TLR and cytokine signaling induce the expression of negative regulators such as MKP-1, which then feedback to inhibit MAP kinase pathways. Post-translationally, ubiquitination and deubiquitination dynamically control the stability and activity of signaling proteins like TRIF and MAVS [8,7]. Phosphorylation by kinases such as IKK and TBK1 can also be reversed by phosphatases, providing another layer of control. Pathogens can modulate these regulatory circuits; for example, Helicobacter pylori alters host innate immune signaling to promote persistence, and foot-and-mouth disease virus VP1 induces autophagic degradation of YTHDF2 to fine-tune IRF3 activity. These regulatory mechanisms ensure that innate immunity is robust but self-limiting.
negative regulation of innate immune response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VAPB | Cancer, antiviral immunity | Knockout and overexpression in cancer cell lines |
| RNF5 | Antiviral response, inflammation | Knockout in macrophages and fibroblasts |
| DUSP1 (MKP-1) | Inflammatory diseases, sepsis | Knockout mice and point-mutation cell models |
| YTHDF2 | Viral infection, interferonopathies | Knockout and tagged knock-in in epithelial cells |
| TRIF (TICAM1) | TLR signaling disorders | Knock-in of ubiquitination-deficient mutants |
Infectious diseases and pathogen evasion
Many pathogens exploit negative regulatory pathways to evade innate immunity. Helicobacter pylori modulates innate immune signaling in gastric epithelial cells, contributing to chronic infection and gastritis. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity, enhancing viral replication. Understanding these evasion strategies can inform host-directed therapies.
Autoinflammatory and autoimmune disorders
Loss of negative regulation can lead to excessive inflammation. MKP-1 (DUSP1) deficiency results in hyperresponsive MAP kinase signaling and increased inflammatory cytokine production, linking it to inflammatory diseases. Similarly, impaired deubiquitination of TRIF or MAVS can cause sustained interferon responses associated with autoimmunity [8,7].
Cancer and antitumor immunity
Negative regulators of innate immunity can suppress antitumor immune responses. VAPB negatively regulates STING-mediated signaling, and its inhibition may enhance antitumor immunity. Targeting negative regulatory nodes such as VAPB or RNF5 could improve cancer immunotherapy [3,7].
Neutrophil-mediated pathology
Neutrophils are key innate immune cells, and their excessive activation contributes to tissue damage. Negative regulation of neutrophil responses is critical to limit collateral damage during infection and inflammation. Dysregulation of these brakes can lead to chronic inflammatory diseases.
From negative regulation of innate immune response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate innate immune response? | CRISPR knockout cell lines followed by LPS or poly(I:C) stimulation |
| Which domain of gene X is required for negative regulation? | Point-mutation knock-in of catalytic-dead or binding-deficient mutants |
| How does gene X interact with signaling partners? | Tagged knock-in (e.g., FLAG, HA) for co-immunoprecipitation |
| Does overexpression of gene X suppress inflammation? | Doxycycline-inducible overexpression in macrophages |
| What is the effect of gene X on pathogen replication? | Knockout cells infected with viruses or bacteria [5,4] |
| Can gene X be targeted for immunotherapy? | Syngeneic tumor models with knockout or overexpression |
How to Study the negative regulation of innate immune response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on innate immune signaling | Identify negative regulators |
| Phosphoproteomics | Changes in protein phosphorylation | Map kinase/phosphatase networks |
| Ubiquitinomics | Ubiquitin chain topology and substrates | Study deubiquitination and degradation |
| RNA-seq | Transcriptional changes | Measure inflammatory gene expression |
| Co-immunoprecipitation | Protein-protein interactions | Validate signaling complexes |
| Luciferase reporter assay | Pathway activity (NF-kB, IFN) | Screen for regulators |
| Live-cell imaging | Subcellular localization and dynamics | Track STING/MAVS trafficking [3,7] |
| Autophagy flux assay | Autophagic degradation | Study YTHDF2 degradation |
CRISPR knockout and overexpression screens
Genome-wide CRISPR knockout screens can identify negative regulators of innate immune response by selecting for cells with enhanced or reduced cytokine production upon stimulation. Overexpression screens complement these by testing candidate genes for suppression of innate immune signaling.
Phosphoproteomics and ubiquitinomics
Mass spectrometry-based phosphoproteomics and ubiquitinomics can map dynamic changes in signaling pathways after innate immune activation, revealing substrates of phosphatases and E3 ligases [1,6]. These methods identify specific phosphorylation and ubiquitination sites that control negative regulation.
RNA sequencing and transcriptomics
RNA-seq of cells with knockout or overexpression of candidate negative regulators reveals global effects on inflammatory gene expression. This approach can uncover feedback loops and identify co-regulated genes.
Imaging and reporter assays
Live-cell imaging of fluorescently tagged signaling proteins (e.g., STING, MAVS) and luciferase reporter assays for interferon or NF-kB activation allow real-time monitoring of negative regulation [3,7]. These methods are useful for validating dynamic regulation in single cells.
How CRISPR Can Be Used to Study GO:0045824 negative regulation of innate immune response
Knockout
CRISPR knockout of candidate negative regulators such as VAPB, RNF5, or DUSP1 can be used to assess their role in dampening innate immune responses. For example, knockout of VAPB enhances STING-mediated signaling, confirming its negative regulatory function. Similarly, RNF5 knockout increases MAVS-mediated antiviral responses.
Point Mutation
Point mutations can dissect catalytic or binding domains required for negative regulation. For instance, mutation of the phosphatase catalytic site in MKP-1 abolishes its ability to dephosphorylate MAP kinases, leading to hyperinflammation. Point mutations in ubiquitination sites of TRIF can prevent its negative regulation by deubiquitination.
Knock-in
Knock-in of tagged or mutant alleles allows precise tracking and functional analysis. Tagged knock-in of TRIF or MAVS enables co-immunoprecipitation to identify interacting partners [8,7]. Knock-in of disease-associated mutations can model human inflammatory disorders.
Overexpression
Overexpression of negative regulators such as VAPB or MKP-1 can suppress innate immune activation, providing a gain-of-function approach to study their inhibitory capacity [3,6]. Inducible overexpression systems allow temporal control of negative regulation.
How EDITGENE Supports negative regulation of innate immune response Research
Researchers studying negative regulation of innate immune response-related genes often need to determine whether a candidate gene is causally involved in dampening innate immunity, which domain or residue is essential, and how its loss or gain of function affects disease-relevant phenotypes. EDITGENE provides end-to-end CRISPR services to answer these questions with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of innate immune response research.
Frequently Asked Questions About negative regulation of innate immune response
What is GO:0045824?
GO:0045824 is the Gene Ontology term for negative regulation of innate immune response, defined as any process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response.
What genes are involved in negative regulation of innate immune response?
Key genes include VAPB, RNF5, DUSP1 (MKP-1), YTHDF2, TRIF, MAVS, and various deubiquitinating enzymes [3,7,6,5,8].
How does negative regulation of innate immune response work?
It works through mechanisms such as proteasomal degradation, deubiquitination, phosphatase-mediated inactivation, and pathogen-driven subversion [1,6,8].
Why is negative regulation of innate immune response important?
It prevents excessive inflammation and autoimmunity while allowing effective pathogen clearance [1,6].
What diseases are linked to defects in negative regulation of innate immune response?
Inflammatory diseases, autoimmunity, cancer, and chronic infections are linked to dysregulation of this process [3,4,6].
How can I study negative regulation of innate immune response?
CRISPR knockout, point mutation, knock-in, overexpression, and CRISPR screens combined with RNA-seq, proteomics, and imaging are common approaches [1,6,3].
What is the role of MKP-1 in innate immunity?
MKP-1 (DUSP1) is a phosphatase that inactivates MAP kinases, thereby negatively regulating inflammatory cytokine production.
How do viruses evade innate immunity via negative regulation?
Viruses such as foot-and-mouth disease virus degrade YTHDF2 to regulate IRF3 and enhance replication.
What is the role of VAPB in innate immunity?
VAPB is a negative regulator of STING-mediated innate immune signaling.
Can CRISPR be used to identify new negative regulators?
Yes, genome-wide CRISPR knockout screens can identify novel negative regulators of innate immune response.
Conclusion
GO:0045824, negative regulation of innate immune response, is a fundamental biological process that balances host defense and immune homeostasis. Its dysregulation contributes to infectious, inflammatory, and malignant diseases. Continued research using CRISPR-based models and multi-omics approaches will uncover new therapeutic targets and deepen our understanding of immune regulation.
References
- 1. Budroni V et al.. 2021. Negative Regulation of the Innate Immune Response through Proteasomal Degradation and Deubiquitination.. Viruses 13(4) PMID: 33808506
- 2. Liew PX et al.. 2019. The Neutrophil's Role During Health and Disease.. Physiol Rev 99(2):1223-1248 PMID: 30758246
- 3. Ji W et al.. 2025. VAPB is a negative regulator of STING-mediated innate immune signaling.. Sci Adv 11(49):eaea3996 PMID: 41337593
- 4. Gobert AP et al.. 2022. Induction and Regulation of the Innate Immune Response in Helicobacter pylori Infection.. Cell Mol Gastroenterol Hepatol 13(5):1347-1363 PMID: 35124288
- 5. Liu H et al.. 2024. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication.. Autophagy 20(7):1597-1615 PMID: 38516932
- 6. Wang X et al.. 2007. Regulation of innate immune response by MAP kinase phosphatase-1.. Cell Signal 19(7):1372-82 PMID: 17512700
- 7. Yan J et al.. 2023. Negatively regulation of MAVS-mediated antiviral innate immune response by E3 ligase RNF5 in black carp.. Fish Shellfish Immunol 134:108583 PMID: 36740081
- 8. Wu X et al.. 2019. Regulation of TRIF-mediated innate immune response by K27-linked polyubiquitination and deubiquitination.. Nat Commun 10(1):4115 PMID: 31511519
